Description
Indication & Scope
Jascayd® is a prescription phosphodiesterase 4B (PDE4B) inhibitor indicated for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). It is also approved for the treatment of adult patients with progressive pulmonary fibrosis (PPF).
- Mechanism: Nerandomilast is a preferential phosphodiesterase 4B (PDE4B) inhibitor that increases intracellular cAMP levels, reducing pro-fibrotic signaling and inflammatory cytokine production to slow the progression of pulmonary fibrosis.
- Drug class: PDE4B inhibitor.
- Clinical use: Treatment of adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
| Generic Name | Nerandomilast Tablets |
| Brand Name | Jascayd® |
| Ingredient | Nerandomilast |
| Dosage Form | Tablet |
| Package | 9 mg × 30 tablets/bottle; 18 mg × 30 tablets/bottle |
| Conditions Treated | Idiopathic pulmonary fibrosis (IPF); Progressive pulmonary fibrosis (PPF) |
| Taboos | Hypersensitivity to nerandomilast or any component of the product; pregnancy |
| Place of origin | Germany |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store below 25°C in a dry place. |
| Manufacturer | Boehringer Ingelheim International GmbH |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20250125;HJ20250126 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 18 mg orally twice daily, approximately 12 hours apart, with or without food. For patients who are unable to tolerate 18 mg twice daily, the dose may be reduced to 9 mg twice daily as recommended in the approved prescribing information.
Time: Tablets should be taken twice daily at approximately 12-hour intervals and swallowed whole or dispersed in water according to the approved prescribing information.
Instructions for use: Nerandomilast may be taken with or without food. No dose adjustment is required for elderly patients or for patients with mild to moderate hepatic impairment or mild to severe renal impairment. Treatment should be continued unless unacceptable toxicity or discontinuation is clinically indicated.
Interaction: Nerandomilast is primarily metabolized by CYP3A4. Concomitant use with strong CYP3A inhibitors or inducers may alter drug exposure and should be managed according to the approved prescribing information.
Side effects: Common adverse reactions include diarrhea, nausea, abdominal pain, decreased appetite, headache, weight loss, dizziness, and fatigue. Most adverse events are mild to moderate, with treatment discontinuation rates comparable to placebo in clinical trials.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What type of drug is Nerandomilast?
It is a preferential phosphodiesterase 4B (PDE4B) inhibitor.
How is Jascayd® administered?
It is taken orally twice daily, approximately 12 hours apart, with or without food.
What are the most common side effects?
The most common adverse reactions include diarrhea, nausea, abdominal pain, headache, decreased appetite, fatigue, and weight loss.
How does Nerandomilast work?
It inhibits PDE4B, increases intracellular cAMP levels, and reduces fibrotic and inflammatory signaling associated with pulmonary fibrosis.
Jascayd® | Nerandomilast | Idiopathic Pulmonary Fibrosis | DengYueRX
INN: Nerandomilast
Indications: Idiopathic pulmonary fibrosis (IPF)
Dosage Form: Tablets
Strength: 9 mg/Tablet; 18 mg/Tablet
